Organoids in Translational Oncology.
Marco TatulloBenedetta MarrelliCaterina BenincasaElisabetta AielloIrina MakeevaBarbara ZavanAndrea BalliniDanila de VitoGianrico SpagnuoloPublished in: Journal of clinical medicine (2020)
Translational medicine aims to translate the most promising preclinical research into clinical practice. Oncology is a continuously growing medical field: the scientific research on cancer biology is currently based on in vitro experiments, carried out on tissue culture plates (TCPs) and other 2D samples. In this context, 3D printing has greatly improved the biofabrication of new biological matrices that mimic the extracellular environments, which may characterize healthy from cancerous tissues. Organoids have recently been described in several reports on scientific literature. The term that better describes such organoids-based tumoral tissues is "tumoroids". Tumoroids are substantially "tumor-like organoids", typically deriving from primary tumors harvested from patients. This topical review aims to give an update on organoids applied in translational medicine, paying specific attention to their use in the investigation of the main molecular mechanisms of cancer onset and growth, and on the most impacting strategies for effective targeted therapies.
Keyphrases
- papillary thyroid
- induced pluripotent stem cells
- end stage renal disease
- clinical practice
- palliative care
- gene expression
- ejection fraction
- healthcare
- chronic kidney disease
- preterm infants
- emergency department
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- stem cells
- bone marrow
- mesenchymal stem cells
- gestational age
- patient reported